sesamyl n-pentylether | 87590-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: sesamyl n-pentylether
• 英文别名: 5-(pentyloxy)benzo[d][1,3]dioxole；5-pentyloxy-benzo[1,3]dioxole；5-Pentyloxy-benzo[1,3]dioxol；1,3-Benzodioxole, 5-(pentyloxy)-；5-pentoxy-1,3-benzodioxole
• CAS: 87590-44-1
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: USLZJQOOOLKIJF-UHFFFAOYSA-N

物化性质

• 沸点：
  284.3±9.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  胡椒醛 在 过氧乙酸 、 氢氧化钾 、 对甲苯磺酸 、 溶剂黄146 作用下， 生成 sesamyl n-pentylether
  参考文献：
  名称：

  Insecticide Synergists, 3,4-Methylenedioxyphenoxy Compounds as Synergists for Natural and Synthetic Pyrethrins

  摘要：

  DOI：

  10.1021/jf60059a002

文献信息

• Cobalt-Catalyzed Decarboxylative Methylation and Ethylation of Aliphatic N-(Acyloxy)phthalimides with Organoaluminum Reagents
  作者：Rui Shang、Yao Fu、Ze-Zhong Wang、Guang-Zu Wang、Bin Zhao

  DOI：10.1055/s-0040-1707946

  日期：2020.7

  A cobalt-catalyzed decarboxylative methylation of aliphatic redox-active esters [N-(acyloxy)phthalimides; RAEs] with trimethylaluminum under mild conditions was developed, providing a method for transforming a carboxylate group into a methyl group without redox fluctuation. Primary and secondary RAEs were both amenable substrates, whereas a tertiary RAE delivered an elimination product. Triethylaluminum

  脂肪族氧化还原活性酯 [N-（酰氧基）邻苯二甲酰亚胺；RAEs] 与三甲基铝在温和条件下的开发，提供了一种将羧酸盐基团转化为甲基基团而没有氧化还原波动的方法。一级和二级 RAE 都是适合的底物，而三级 RAE 提供消除产物。三乙基铝也用于提供脱羧乙基化产物。
• Devakumar, C.; Saxena, V. S.; Mukerjee, S. K., Agricultural and Biological Chemistry, 1985, vol. 49, # 3, p. 725 - 730
  作者：Devakumar, C.、Saxena, V. S.、Mukerjee, S. K.

  DOI：——

  日期：——
• Arginase Inhibitors and Methods of Use
  申请人：AstraZeneca AB

  公开号：US20200223871A1

  公开（公告）日：2020-07-16

  The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.